64 Cu-Plerixafor

N/A

Report date: 2025/11/24 11:49:21

NMEFirst In Class

Base Information

Drug Name64 Cu-Plerixafor

Drug Alias NameN/A

ClassificationSmall molecules > Heterocyclic drugsRadiation-emitting products > Nuclides > Copper > 64CuRadiation-emitting products > Radionuclide Drug Conjugates +[5]

Mechanisms of ActionC-X-C motif chemokine receptor 4 antagonists

TargetsC-X-C motif chemokine receptor 4

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesNational Institute Of Allergy And Infectious Diseases (Niaid)Georgetown Lombardi Comprehensive Cancer Center

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGeorgetown Lombardi Comprehensive Cancer Center National Institute Of Allergy And Infectious Diseases (Niaid)

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A